{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"16","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"PFS based on the Kaplan-Meier method is defined as the duration of time \\[months (m)\\] from study entry to documented disease progression (PD) or death. Participants alive without PD are censored at the date of last disease assessment. For intrinsic pontine brainstem gliomas, only one lesion/mass is present at diagnosis. Comparisons of maximal 2-dimensional measurements, TxW (product of the longest diameter \\[width (W)\\] and its longest perpendicular diameter \\[transverse (T)\\]) are used to assess response for this target lesion. PD is 25% or more increase, taking as reference the smallest product observed since the start of treatment, or the appearance of one or more new lesions.","dispersionType":"Full Range","groups":[{"description":"Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).\n\nTreatment directed based on tumor biopsy results requires classification of patients into 1 of 4 potential cohorts: O\\^6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status (negative versus positive) and epidermal growth factor receptor (EGFR) overexpression status (negative versus positive).","id":"OG000","title":"All Patients Starting Assigned Chemoradiation"}],"paramType":"MEDIAN","populationDescription":"The analysis population is comprised of the subset of participants who underwent surgical biopsy, obtained a molecularly-based treatment assignment and started assigned chemoradiation therapy. The PFS was aggregated across cohorts per statistical analysis plan to evaluate the effect of the \"molecular strategy\".","reportingStatus":"POSTED","timeFrame":"Disease assessments using a standard CNS imaging protocol occurred chemoradiation cycles 1 and 2, every other maintenance cycle, every 3 months post-treatment year 1 then annually until PD or therapy change; In this study cohort, follow-up was up to 34m.","title":"Median Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}